New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
07:06 EDTMYGNMyriad Genetics Prolaris test predicts risk of prostate cancer recurrence
Myriad Genetics announced that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
16:22 EDTMYGNMyriad Genetics sees FY15 adjusted EPS $1.44-$1.46, consensus $1.52
Subscribe for More Information
16:22 EDTMYGNMyriad Genetics sees Q4 adjusted EPS 40c-42c, consensus 49c
Sees Q4 revenue $187M-$189M, consensus $197.97M. The company said, "The primary reasons for this guidance revision are related to the impact of severe weather on our fiscal third-quarter revenue, a delay in Medicare reimbursement for Prolaris until the first quarter of fiscal year 2016, and a delay in international reimbursement."
16:21 EDTMYGNMyriad Genetics reports Q3 adjusted EPS 40c, consensus 39c
Subscribe for More Information
15:02 EDTMYGNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Mylan (MYL), consensus 69c... Devon Energy (DVN), consensus 26c... Pioneer Natural Resources (PXD), consensus 8c... CenturyLink (CTL), consensus 59c... Plains All American Pipeline (PAA), consensus 54c... Fiserv (FISV), consensus 86c... Electronic Arts (EA), consensus 25c... Plains GP Holdings (PAGP), consensus 14c... Agrium (AGU), consensus 34c... ONEOK (OKE), consensus 36c... Western Gas Partners (WES), consensus 44c... Digital Realty Trust (DLR), consensus $1.23... Newfield Exploration (NFX), consensus 8c... Community Health Systems (CYH), consensus 66c... SolarCity (SCTY), consensus (1.58)... Qiagen (QGEN), consensus 22c... Zillow (Z), consensus (11c)... Groupon (GRPN), consensus 1c... RenaissanceRe Holdings (RNR), consensus $2.43... Gulfport Energy (GPOR), consensus (9c)... SM Energy (SM), consensus 31c... Herbalife (HLF), consensus $1.01... Kinross Gold (KGC), consensus 0c... Myriad Genetics (MYGN), consensus 39c... Delek US (DK), consensus 10c... IAMGOLD (IAG), consensus (4c)... Halcón Resources (HK), consensus (2c).
06:15 EDTMYGNMyriad Genetics fights to sustain business model, WSJ reports
Subscribe for More Information
May 4, 2015
09:50 EDTMYGNLeerink to hold next-generation sequencing meeting
Subscribe for More Information
07:12 EDTMYGNAmerican Congress of Obstetrics and Gynecology
2015 ACOG Annual Clinical & Scientific Meeting is being held in San Francisco on May 2-6.
May 3, 2015
17:19 EDTMYGNMyriad Genetics CEO 'actively' searching for acquisitions, WSJ says
In a Wall Street Journal interview, Myriad (MYGN) CEO Mark Capone said the company is currently developing tests for diabetes, autoimmune disorders, and neuropsychiatric conditions, while also "actively looking" for acquisitions. In a separate interview, Robert McDonough, head of Aetna's (AET) clinical policy research, remarked that Myriad should "eventually" be able to have its Vectra DA rheumatoid arthritis test covered by insurance. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use